Evidence map›Paper›PMID 40346320›Full record

ArticleClinical and experimental medicine2025

Immunoglobulin a vasculitis with central nervous system involvement: analysis of 10 cases.

Ziyun Guo, Shaojing Li, Chang Liu, Zhongyi Zhu, Panpan Wang, Yan Yang, Lina Du

Abstract read
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ziyun GuoDepartment of Chinese Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
Shaojing LiDepartment of Pediatrics, China Aerospace Science & Industry Corporation 731 Hospital, Beijing, 100074, China.
Chang LiuDepartment of Chinese Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
Zhongyi ZhuDepartment of Chinese Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
Panpan WangDepartment of Pediatrics, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310007, China.
Yan YangDepartment of Chinese Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China. yy2303@sina.com.ORCID http://orcid.org/0000-0003-1070-9614
Lina DuDepartment of Chinese Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China. linadu2007@126.com.ORCID http://orcid.org/0000-0002-4173-1585

Funding

Natural Science Foundation of Beijing Municipality 7212169The Capital's Funds for Health Improvement and Research 2022-2-2097
6 · The paper itself

Abstract

Immunoglobulin A vasculitis (IgAV) is a systemic inflammatory disease that affects small blood vessels. Central nervous system (CNS) involvement in IgAV is rare. This study analyzed the clinical characteristics of IgAV patients combined with CNS damage in children. Furthermore, the study made a comparison between the characteristics of IgAV patients with and without CNS damage, and initially explored the potential predictors for IgAV patients with CNS damage. A retrospective analysis was conducted on a cohort of 50 children diagnosed with IgAV and admitted to Beijing Children's Hospital from 2016 to 2019. The study encompassed a review of the clinical presentations, laboratory test results, imaging findings, therapeutic interventions, and prognoses of 10 children with IgAV who exhibited CNS involvement. These 10 cases were then compared with a group of 40 children with IgAV without CNS involvement. The prevalence of IgAV with CNS manifestations was 0.2%. The median age was 11.6 years, with a male-to-female ratio of 7:3. All CNS symptoms appeared after the purpuric rash. The mean period from IgAV onset to the development of neurological symptoms was 12.2 days (range: 1-27 days). Seizures were the most common neurological manifestation, with impaired consciousness and predominant convulsions. Other symptoms included headache, visual impairment, dysarthria, dyskinesia, and emotional irritation. The main abnormalities found on brain magnetic resonance imaging (MRI) were unilateral or bilateral abnormal focal signals, cortical and subcortical white matter edema, and thrombosis of the venous sinus. Glucocorticoid therapy and intravenous immunoglobulins were used to treat CNS damage caused by IgAV. All patients showed clinical improvement without recurrent neurological symptoms or sequelae. Statistically differences were identified in in terms of age, gastrointestinal damage, WBC count, NLR, ALB, C3 levels, and the CD4/CD8 ratio in IgAV patients with CNS damage when compared to those without CNS damage. Multivariable logistic regression analysis shows that age, NLR and C3 Levels are predictors of IgAV with CNS damage. CNS involvement in IgAV is a rare complication. Its clinical manifestations are diverse and vary in severity, and its diagnosis is exclusionary. Brain MRI is beneficial for diagnosis and follow-up. Steroid therapy is important for treating IgAV-associated CNS involvement. Age, NLR and C3 Levels are predictors of IgAV with CNS damage.

Indexed as

IgA VasculitisVasculitis, Central Nervous SystemAdolescentBrainCase-Control StudiesChildChild, PreschoolFemaleGlucocorticoidsHumansImmunoglobulins, IntravenousMagnetic Resonance ImagingMalePrognosisRetrospective StudiesSeizuresGlucocorticoidsImmunoglobulins, IntravenousCentral nervous system involvementImmunoglobulin A vasculitisIntravenous ImmunoglobulinsMethylprednisolonePotential predictorsSeizure

Identifiers

PMID40346320
PMCPMC12064608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.